[THE INVESTOR] Yozma Group chairman Yigal Erlich on June 30 hinted at new funding worth up to US$100 million in Korea’s biotech venture firms.
Yozma Group chairman Yigal Erlich
The head of the leading venture capitalist based in Israel was visiting Seoul to attend a conference among bioscience experts and industry officials.
Touting Korea’s advanced medical techniques, he showed expectations about the growth potential of the nation’s biotech industry.
During his visit, Yozma Group also signed a memorandum of understanding with the Korea Bio Technology Organization to nurture some 1,000 biotech start-ups.